Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: A therapeutic role for complement inhibitors?

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Hsu, Stephen I Hong ^a,b,c,e   Couser, William G ^d  

^a National Kidney Foundation   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; GROWTH FACTOR;

CELL DAMAGE; CELLULAR IMMUNITY; CHRONIC KIDNEY FAILURE; COMPLEMENT ACTIVATION; CONFERENCE PAPER; ENDOTHELIUM; FIBROGENESIS; GLOMERULOPATHY; HUMAN; HUMORAL IMMUNITY; IMMUNE COMPLEX NEPHRITIS; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; MICROVASCULATURE; NEPHROSIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA;

EID: 0013443651     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Couser W: Pathogenesis of glomerulonephritis. Kidney Int 44[Suppl 42]: S19-S26, 1993
2. Burton C, Harris K: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27: 765-775, 1996
3. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
4. Keane W: Proteinuria: Its clinical importance and role in progressive renal disease. Am J Kidney Dis 35[Suppl 1]: S97-S 105, 2000
5. Klahr S, Levey A, Beck G, Caggiula A, Hunsicker L, Kusek J, Striker G: The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884, 1984
6. Group TG: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
7. HOPE Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
8. Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins R, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
9. Brenner B, Cooper M, De Zeeuw D, Keane W, Mitch W, Parving H-H, Remuzzi G, Snapinn S, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
10. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
11. Kriz W: Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 57: 189, 195, 2002
12. Kang K-H, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner G, Johnson R: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13: 806-816, 2002
13. Russo L, Bakris G, Comper W: Renal handling of albumin: A critical review of basic concepts and perspective. Am J Kidney Dis 39: 899-919, 2002
14. Matsuo S, Morita Y, Mizuno M, Nishikawa K, Yuzawa Y: Proteinuria and damage to tubular cells: Is complement a culprit? Nephrol Dial Transplant 13: 2723-2726, 1998
15. Sheerin S, Sacks S: Chronic interstitial damage in proteinuria: Does complement mediate tubulointerstitial damage? Kidney Blood Press Res 22: 47-52, 1999
16. Tang S, Lai K, Sacks S: Role of complement in tubulointerstitial injury from proteinuria. Kidney Blood Press Res 25: 120-126, 2002
17. Risdon R, Sloper J, de Wardener H: Relations between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 2: 363-366, 1968
18. Striker G, Schainuck L, Cutler R, Benditt E: Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum Pathol 1: 615-630, 1970
19. Schainuck L, Striker G, Cutler R, Benditt E: Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1: 1970
20. Mackensen-Haen S, Bader R, Grund K, Bohle A: Correlations between renal cortical interstitial fibrosis, atrophy of proximal tubules and impairment of glomerular filtration rate. Clin Nephrol 15: 167-171, 1981
21. Nath K: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20:1-17, 1992
22. Hruby Z, Smolska D, Filipowski H, Rabczynski J, Cieslar E, Kopec W, Dulawa J: The importance of tubulointerstitial injury in the early phase of primary glomerular disease. J Intern Med 243: 215-222, 1998
23. Eddy A: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5: 1273-1287, 1994
24. Benigni A, Zoja C, Remuzzi G: Biology of disease: The renal toxicity of sustained glomerular protein traffic. Lab Invest 73: 461-468, 1995
25. Olbricht C, Cannon J, Garg L, Tisher C: Activities of cathepsins B and L in isolated nephron segments from proteinuric and nonproteinuric rats. Am J Physiol 250: F1055-1062, 1986
26. Alfrey A: Toxicity of tubule fluid iron in the nephrotic syndrome. Am J Physiol 263: F637-F641, 1992
27. Kees-Folts D, Sadow J, Schreiner G: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 45: 1697-1709, 1994
28. Johnson T, Griffin M, Thomas G, Skill J, Cox A, Yang B, Nicholas B, Birckbichler P, Muchaneta-Kubara C, El Nahas A: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 99: 2950-2960, 1997
29. Tang S, Leung J, Tsang A, Lan H, Chan T, Lai K: Transferrin up-regulates chemokine synthesis by human proximal tubular epithelial cells: Implications on mechanism of tubuloglomerular communication in glomerulopathic proteinuria. Kidney Int 61: 1655-1665, 2002
30. Morita Y, Nomura A, Yuzawa Y, Nishikawa K, Hotta N, Shimizu F, Matsuo S: The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am Soc Nephrol 8: 1363-1372, 1997
31. Nangaku M, Pippin J, Couser W: Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 10: 2323-2331, 1999
32. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S: Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 11: 700-707, 2000
33. Nangaku M, Pippin J, Couser W: C6 mediates chronic progression of tubulointerstitial damage in rat with remnant kidneys. J Am Soc Nephrol 13: 928-936, 2002
34. Nath K, Hostetter M, Hostetter T: Pathophysiology of chronic tubulo-interstitial disease in rats: interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76: 667-675, 1985
35. Nath K, Hostetter M, Hostetter T: Ammonia-complement interaction in the pathogenesis of progressive renal injury. Kidney Int 36[Suppl 27]: S52-S54, 1989
36. Clark E, Nath K, Hostetter M, Hostetter T: Role of ammonia in progressive interstitial nephritis. Am J Kidney Dis 5[Suppl 1]: 15-19, 1991
37. Baker P, Adler S, Yang Y, Couser W: Complement activation by heat-killed human kidney cells: Formation, activity, and stabilization of cell-bound C3 convertases. J Immunol 133: 877-881, 1984
38. Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G: Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 45: 451-460, 1994
39. David S, Biancone L, Caserta C, Bussolati B, Cambi V, Camussi G: Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant 12: 51-56, 1997
40. Khan T, Sinniah R: Role of complement in renal tubular damage. Histopathology 26: 351-356, 1993
41. Montinaro V, Lopez A, Monno R, Cappiello V, Manno C, Gesualdo L, Schena F: Renal C3 synthesis in idiopathic membranous nephropathy: Correlation to urinary C5b-9 excretion. Kidney Int 57: 137-146, 2000
42. Schulze M, Baker P, Perkinson D, Johnson R, Ochi R, Stahl R, Couser W: Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int 35: 60-68, 1989
43. Schulze M, Donadio Jr V, Pruchno C, Baker P, Johnson R, Stahl R, Watkins S, Martin D, Wurzner R, Gotze O, Couser W: Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 40: 533-538, 1991
44. Brenchley P, Coupes B, Short C, O'Donoghue D, Ballardie F, Mallick N: Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int 41: 933-937, 1991
45. Kon S, Coupes B, Short C, Solomon L, Raftery M, Mallick N, Brenchley P: Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 48: 1953-1958, 1995
46. Zhou W, Marsh J, Sacks S: Intrarenal synthesis of complement. Kidney Int 59: 1227-1235, 2001
47. Nomura A, Morita Y, Maruyama S, Hotta N, Nadai M, Want L, Hasegawa T, Matsuo S: Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 151: 539-547, 1997
48. Hori Y, Yamada K, Hanafusa N, Okuda T, Okada N, Miyata T, Couser W, Kurokawa K, Fujita T, Nangaku M: Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria. Kidney Int 56: 2096-2106, 1999
49. Hebert M-J, Takano T, Papayianni A, Rennke H, Minto A, Salant D, Carroll M, Brady H: Acute nephrotoxic serum nephritis in complement knockout mice: Relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 13: 2799-2803, 1998
50. Camussi G, Rotunno M, Segoloni G, Brentjens J, Andres G: In vitro alternative pathway activation of complement by the brush border of proximal tubules of normal rat kidney. J Immunol 128: 1659-1663, 1982
51. Camussi G, Tetta C, Mazzucco G, Vercellone A: The brush border of proximal tubules of normal human kidney activates the alternative pathway of the complement system in vitro. Ann NY Acad Sci 420: 321-324, 1983
52. + transport in the kidney. Kidney Int 40[Suppl 33]: S95-102, 1991
53. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl K, Sahu A, Lambris J: Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 92: 1661-1667, 1998
54. Kilgore K, Naylor K, Tanhelco E, Park J, Booth E, Washington R, Lucchesi B: The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 285: 987-994, 1998
55. Marshall J, Wellstein A, Rae J, DeLap R, Phipps K, Hanfelt J, Yumbam M, Sun J, Duchin K, Hawkins M: Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin Cancer Res 3[12 Pt 1]: 2347-2354, 1997
56. Ueda N, Midorikawa A, Ino Y, Oda M, Nakamura J, Suzuki S, Kurumi M: Inhibitory effects of newly synthesized active center-directed trypsin-like serine protease inhibitors on the complement system. Inflamm Res 49: 42-46, 2000
57. Couser W, Johnson R, Young B, Yeh C, Toth C, Rudolph A: The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 5: 1888-1894, 1995
58. Heller A, Kunz M, Samakas A, Haase M, Kirschfink M, Koch T: The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock 13: 285-290, 2000
59. Nangaku M: Complement regulatory proteins in glomerular diseases. Kidney Int 54: 1419-1428, 1998
60. Fodor W, Rollins S, Guilmette E, Setter E, Squinto S: A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. J Immunol 155: 4135-4138, 1995
61. Lublin D, Coyne K: Phospholipid anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement mediated cell damage. J Exp Med 174: 35-44, 1991
62. Welch T: The complement system in renal diseases. Nephron 88: 199-204, 2001
63. Rioux P: TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2: 364-371, 2001
64. Kirschfink M: Controlling the complement system in inflammation. Immunopharmacology 38: 51-62, 1997
65. Marsh J, Pratt J, Sacks S: Targeting the complement system. Curr Opin Nephrol Hypertens 8: 557-562, 1999
66. Begum N, Murakami Y, Mikata S, Matsumoto M, Hatanaka M, Nagasawa S, Minoshita T, Seya T: Molecular remodelling of human CD46 for xenotransplantation: Designing a potent complement regulator without measles virus receptor activity. Immunology 100: 131-139, 2000
67. Matis L, Rollins S: Complement-specific antibodies: Designing novel anti-inflammatories. Nat Med 1: 839-842, 1995
68. Baker P, Ochi R, Schulze M, Johnson R, Campbell C, Couser W: Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 135: 185-194, 1989
69. Cybulsky A, Quigg R, Salant D: The membrane attack complex in complement-mediated glomerular epithelial cell injury: formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy. J Immunol 137: 1511-1516, 1986
70. Savin V, Johnson R, Couser W: C5b-9 increases albumin permeability of isolated glomeruli in vitro. Kidney Int 46: 382-387, 1994
71. Wang Y, Rollins S, Madri J, Matis L: Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Molec Immunol 92: 8955-8959, 1995
72. 1 mice after treatment with a blocking monoclonal antibody specific for complement component 5. Proc Natl Acad Sci USA 93: 8563-8568, 1996
73. Evans M, Rollins S, Wolff D, Rother R, Norin A, Therrien D, Grijalva G, Mueller J, Nye S, Squinto S, Wilkins J: In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Molec Immunol 32: 1183-1195, 1995
74. Thomas T, Rollins S, Rother R, Giannoni M, Hartman S, Elliott E, Nye S, Matis L, Squinto S, Evans M: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Molec Immunol 33: 1389-1401, 1996